CD274 and breast cancer: Immunohistochemistry staining for PD-L1 is employed; however, neither the antibodies nor the scoring assessments are standardized, and additional biomarkers are still needed to optimize PD-1/PD-L1 targeting therapeutics in BC [79,80,81].